参考资料:1. Benson AB, Venook AP, Al-Hawary MM, et al. Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN 2019; 17(9): 1109-33.2. 沈琳, 曹晖, 秦叔逵, et al. 中国胃肠间质瘤诊断治疗共识(2017年版). 肿瘤综合治疗电子杂志 2018; 4(01): 31-43.3. Serrano C, Mariño-Enríquez A, Derrick L Tao , et al. Complementary Activity of Tyrosine Kinase Inhibitors Against Secondary Kit Mutations in Imatinib-Resistant Gastrointestinal Stromal Tumours. Br J Cancer. 2019 Mar,120(6):612-620.4. Smith BD, Kaufman MD, Lu WP, et al. Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants. Cancer cell, 2019, 35(5): 738-751. e9.5. INVICTUS: A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ripretinib as ≥4th-Line Therapy In Patients With AdvanCed Gastrointestinal Stromal TUmorS (GIST) Who have Received Treatment With Prior Anticancer Therapies. 2019 ESMO, LBA87.6. Blay JY, Serrano C , Heinrich MC, et al. Ripretinib in Patients With Advanced Gastrointestinal Stromal Tumours (INVICTUS): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial. Lancet Oncol, 2020 Jun 5;S1470-2045(20)30168-6. doi: 10.1016/S1470-2045(20)30168-6.7. Joseph CP, Abaricia SN, Angellis MA, et al. Avapritinib for the treatment of GIST: analysis of efficiency, safety, and patient management strategies at the recommended phase 2 dose (abstract no. 3258000 and poster). In: Connective Tissue Oncology Society annual meeting. 2019.